Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT

Pfizer vaults into sickle cell market as GBT deal confirmed

ODM standard for CRF design

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Digital health app linked to better outcomes in heart failure

Koselugo

astrazeneca-sign

Market Access/ News/ News

AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis

Phil Taylor AstraZeneca, EU, Koselugo, Merck & Co, Neurofibromatosis, regulatory approval, Selumetinib 0 Comment

The European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to

X

AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis

https://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Bayer bags swift OK for Nubeqa in metastatic prostate cancer
Pfizer bid for sickle cell drug developer GBT said to be imminent
AZ gets FDA nod for Enhertu in first HER2-low cancer
Digital health app linked to better outcomes in heart failure
Pfizer vaults into sickle cell market as GBT deal confirmed

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com